



## AVITA MEDICAL, INC. (ASX:AVH)

### Cleansing Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

---

**Valencia, California, USA, 25 August 2025 and Melbourne, Australia, 26 August 2025:** On 20 August 2025 (United States) / 21 August 2025 (Australia) AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL) (the “**Company**”), a leading therapeutic acute wound care company delivering transformative solutions, issued a total of 27,200 fully paid shares of common stock in the Company (**New Securities**). These securities were issued as a result of Restricted Stock Units being converted into Common Stock.

The New Securities will be quoted on NASDAQ, but may be converted into CHES Depositary Interests (**CDIs**) in the Company quoted on ASX at any time by the relevant holder. The Company seeks to rely on an exemption under section 708A of the *Corporations Act 2001* (Cth) (**Corporations Act**) with respect to the sale of any CDIs which are issued on conversion of the New Securities (in the instance that such conversion occurs).

The Company gives this Cleansing Notice under Section 708A(5)(e) of the Corporations Act, as modified by ASIC Corporations (Offers of CHES Depositary Interests) Instrument 2025/180.

The New Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

As of the date of this notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- Sections 674 and 674A of the Corporations Act.

As of the date of this Cleansing Notice, there is no information that is “excluded information” within the meaning of Section 708A(7) and Section 708A(8) of the Corporations Act.

Authorized for release by the Chief Financial Officer of the Company.

#### ABOUT AVITA MEDICAL, INC.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

#### Forward-Looking Statements

*Statements in this notice may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant*

*risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "guidance," "intend," "look forward," "may," "outlook," "project," "target," "will," "would," and similar words or expressions, and the use of future dates. These statements are made as of the date of this notice, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward- looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.*

**Investor & Media Contact:**

Ben Atkins

Phone +1-805-341-1571

[investor@avitamedical.com](mailto:investor@avitamedical.com)

[media@avitamedical.com](mailto:media@avitamedical.com)

###